EpiCheck is a highly innovative product for detection of cancer in liquid biopsy samples, using a panel of various methylation biomarkers
Location: Israel, Center District, Rehovot
Total raised: $137.92M
Investors 4
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Aurum Vent... | aurum.co.i... |
| - | Gefen Capi... | gefencapit... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 01.02.2022 | - | $77M | - |
| 26.04.2021 | - | $55M | - |
| 31.07.2018 | - | $2.92M | - |
| 25.05.2016 | - | $3M | - |
Mentions in press and media 13
| Date | Title | Description |
| 13.09.2024 | Breaking Barriers: The Fight Against Lymphoma and Bladder Cancer | In the realm of cancer awareness, two significant events recently unfolded, shining a light on the emotional and physical battles faced by patients. On one hand, World Lymphoma Awareness Day (WLAD) took center stage, while on the other, a g... |
| 09.09.2024 | A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe | Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recu... |
| 18.01.2022 | Nucleix Closes $55M Funding Round | San Diego-based Nucleix, a company revolutionizing cancer treatment by detecting the disease earlier via liquid biopsy, has secured $55 million from a syndicate of leading life science investors in an oversubscribed financing round. The rou... |
| 26.04.2021 | Nucleix Raises $55M for Early Detection of Lung Cancer | In April, Nucleix secured $55 million in funding to develop its Lung EpiCheck platform for earlier detection of lung cancer. Image courtesy of Nucleix. Nucleix, a liquid biopsy company that is innovating cancer treatment with earlier diseas... |
| 08.04.2021 | Liquid biopsy maker Nucleix rakes in $55M to develop blood tests to detect lung cancer early | It’s full steam ahead for Nucleix’s blood test for lung cancer detection, thanks to an influx of cash in the Israeli company’s latest round of funding. The liquid biopsy maker closed its oversubscribed $55 million financing on April 7. RA C... |
| 08.04.2021 | Liquid biopsy maker Nucleix rakes in $55M to develop blood tests to detect lung cancer early | It’s full steam ahead for Nucleix’s blood test for lung cancer detection, thanks to an influx of cash in the Israeli company’s latest round of funding. Free Infographic Download 7 Areas to Evaluate When Selecting Your Clinical Adjudication ... |
| 07.04.2021 | Nucleix has secured a $55M financing round to advance its technology, Lung EpiCheck, for early detection of lung cancer | - |
| 07.04.2021 | Nucleix Nabs $55M For Lung Cancer Detection | San Diego-based Nucleix, a startup which is developing liquid biopsy technology for early detection of lung cancer, has raised $55M in a funding round, the company announced this morning. The company said the funding was led by RA Capital M... |
| 07.04.2021 | Nucleix Secures $55 Million Funding to Advance Lung EpiCheck® for Early Detection of Lung Cancer | - |
| 07.04.2021 | Nucleix Secures $55M in Funding | Nucleix, a Rehovot, Israel- and San Diego, CA-based liquid biopsy company, secured $55m in funding. The round was led by RA Capital Management, with participation from new investors including funds and accounts managed by BlackRock, Lilly A... |
Show more